A landmark paper published in 2002 set the standard for Targeted Temperature Management (TTM)  by having hospitals use TTM protocols to "cool" patients for a period of time after cardiac arrest to improve neurologic outcomes. On June 17th, 2021, the TTM-2 study was published and changed this standard. What is the future of the TTM modality in cardiac arrest patients?

Redeem your CPE or CME credit here!

References and resources:
Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021 Jun 17;384(24):2283-2294. doi: 10.1056/NEJMoa2100591. PMID: 34133859.

Continuing Education Information:
Learning Objectives:
1. Describe the TTM-2 study
2. Discuss the theoretical benefits of maintaining a normal or low body temperature immediately following cardiac arrest.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-263-H01-P
Initial release date: 8/17/21
Expiration date: 8/17/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Do psychedelics treat mental illness? In this GameChanger episode host, Geoff Wall and guest, Sarah Grady, a psychiatric pharmacist, discuss a recent NEJM article comparing psilocybin (magic mushrooms) to escitalopram.

Guest:
Sarah Grady, PharmD
Drake University

Redeem your CPE or CME credit here with your GameChangers Subscription!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964


References and resources:
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.

Continuing Education Information:
Learning Objectives:
1. Discuss a recent study comparing psilocybin to escitalopram in depression
2. Identify potential patients that could benefit from psilocybin based on the study

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-231-H01-P
Initial release date: 8/3/21
Expiration date: 8/3/22
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this activity.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The delta variant of COVID-19 has put the US in the precarious position of a fourth wave of the disease -- how efficacious are our vaccines against this variant? Also, are any new treatments for early COVID-19 being studied to help continue the fight? Find out more in this episode!

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30. PMID: 34192428; PMCID: PMC8262622.

Rossignol J, Matthew C, Oaks J, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441

Continuing Education Information:
Learning Objectives:
1. Discuss the differences in effectiveness between the mRNA and adenovirus vaccines for the delta variant of COVID-19
2. Describe the use of nitazoxanide in mild to moderate COVID-19 and barriers to its use

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-XXX-H01-P
Initial release date: 8/31/21
Expiration date: 8/24/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.

Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf

Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care?

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. doi:10.1001/jamacardio.2021.1437

Continuing Education Information:
Learning Objectives:
1. Define QALY
2. Discuss the cost-effectiveness of dapagliflozin in heart failure

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-264-H01-P
Initial release date: 7/20/21
Expiration date: 7/20/2022
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

New asthma guidelines came out in 2020, yet the answer to triple or dual inhaler therapy wasn't explicitly answered. In this episode host, Geoff Wall and guest, Jake Galdo discuss the role of triple inhaler (ICS-LABA-LAMA) in the management of severe persistent and uncontrolled asthma.

Redeem your CPE or CME credit with a GameChangers Subscription here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA. 2021 May 19:e217872. doi: 10.1001/jama.2021.7872. Epub ahead of print. PMID: 34009257; PMCID: PMC8135065.

Continuing Education Information:
Learning Objectives:
1. Discuss a recent study comparing triple to dual inhaler therapy in asthma
2. Describe the adverse drug events associated with triple inhaler therapy in asthma
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-230-H01-P
Initial release date: 7/13/21
Expiration date: 7/13/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The recently published ADAPTABLE study seeks to answer, definitively, a long held question: What is the correct dose of aspirin to improve outcomes in secondary prevention of cardiovascular disease? Also, more information about PCORnet, which is referenced in the article and during the episode, may be found here: https://pcornet.org/

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 May 15. doi: 10.1056/NEJMoa2102137. Epub ahead of print. PMID: 33999548.

Continuing Education Information:
Learning Objectives:
1. Describe the outcomes and design of the ADAPTABLE study
2. Discuss some of the limitations of this trial in its application to specific patients

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-229-H01-P
0.50 AMA PRA Category 1 Credits™
Initial release date: 7/6/21
Expiration date: 7/6/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Vaccines are the mainstay of care in the COVID-19 pandemic. However, patients may still become infected and need treatment options. Two studies have evaluated the role of inhaled budesonide for the early treatment of outpatient COVID-19 infections. Can budesonide hasten the resolution of symptoms or prevent hospitalizations?

Redeem your CPE or CME credit here!

References and resources:
Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine. April 2021. doi:10.1016/s2213-2600(21)00160-0

Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv. Published online January 1, 2021:2021.04.10.21254672. doi:10.1101/2021.04.10.21254672

Continuing Education Information:
Learning Objective: Identify the appropriate patient population for inhaled budesonide in the treatment of COVID-19
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-228-H01-P
0.50 AMA PRA Category 1 CreditsTM.(the TM needs to be super scripted)
Initial release date: 6/29/21
Expiration date: 6/29/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Diuretics, thiazide, and loop are critical medications for a number of disease states. Yet, they are often used inappropriately, either on the wrong dose or schedule or prescribed in patients who may not benefit from diuretics. This episode takes a look at diuretic pearls and how to get the most out of these medications.

Resources:
Ali S, Jung S, Nandkeolyar S, Stoletniy L, Sakr A, Verbrugge FH, Hilliard A, Abramov D. Inpatient Diuretic Management of Acute Heart Failure: A Practical Review. Am J Cardiovasc Drugs. 2021 Mar 12. doi: 10.1007/s40256-020-00463-5.

Sinha AD, Agarwal R. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clin J Am Soc Nephrol. 2019 May 7;14(5):757-764. doi: 10.2215/CJN.04330418.

Continuing Education Information:
Learning Objective: Identify an appropriate dose and schedule for loop diuretics.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-211-H01-P
0.50 AMA PRA Category 1 Credits™.
Initial release date: 6/8/21
Expiration date: 6/8/22
Complete CPE & CME details can be found at: https://network.ceimpact.com/plans/142054?bundle_token=2c8f01a0dd5d1a330a87ed726ba0af93

Follow CEimpact on Social Media:
LinkedIn
Instagram

Longer antibiotics are associated with increased costs and adverse effects and increase the potential for bacterial resistance. A recent paper in the Lancet describes a study conducted in France comparing the outcomes of patients with community-acquired pneumonia (CAP) who are hospitalized but not critically ill with a short course of antibiotics (3 days) compared to standard treatment (8 days). The study found that the short course was non-inferior to the longer course of antibiotics and may have implications for treating the common infection.

References and resources:
Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021 Mar 27;397(10280):1195-1203. doi: 10.1016/S0140-6736(21)00313-5. PMID: 33773631.

Continuing Education Information:
Learning Objective: Discuss the difference between 3-day and 8-day antibiotic use in patients with community-acquired pneumonia.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-210-H01-P
0.50 AMA PRA Category 1 CreditsTM
Initial release date: 6/1/21
Expiration date: 6/1/22
Complete CPE & CME details can be found at here

Follow CEimpact on Social Media:
LinkedIn
Instagram